Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivity  by Hoffman, Aaron et al.
Kidney International, Vol. 45 (1994), pp. 556—560
Urinary excretion rate of endothelin- 1 in patients with essential
hypertension and salt sensitivity
AARON HOFFMAN, EHUD GROSSMAN, DAVID S. GOLDSTEIN, JOHN R. GILL, JR.,
and HARRY R. KEISER
Transplant Unit, Rambam Medical Center, and The Technion, Israel Institute of Technology, Haifa, Israel; and Hypertension-Endocrine
Branch, National Heart, Lung and Blood Institute, NIH, Bethesda Maryland, USA
Urinary excretion rate of endothelin-1 in patients with essential hyper-
tension and salt sensitivity. To assess the possible role of ET-l in the
pathogenesis of hypertension and salt sensitivity levels of immunore-
active endothelin-l (irET-l) were measured in plasma and urine of 17
patients with essential hypertension and in 19 normotensive control
subjects. Effects of alterations in dietary sodium content on urinary
irET-1 levels also were assessed. Plasma levels of irET-l did not differ
between the hypertensives and normotensive groups (1.1 0.3 and 1.3
0.1 pg/mI). Urine samples of both groups contained high concentra-
tions of irET- 1. However, the mean daily urinary excretion of irET- I in
the hypertensives was less than one-third that in controls (29 3 vs. 109
21 ng/day, respectively, P < 0.01). Changing dietary sodium content
in the hypertensives had no effect on mean irET-l excretion. However,
on either low, intermediate, or high salt diet, "salt sensitive" hyper-
tensives had lower levels of the peptide than "salt resistant" patients
(23 3 vs. 36 5 ng/day, respectively, P < 0.05). The data
demonstrate a marked reduction in irET-l excretion in patients with
essential hypertension, despite normal plasma levels of the peptide.
Since ET-1 has diuretic and natriuretic properties, the decreased renal
excretion of ET-I may be of relevance to the pathophysiology of
hypertension and salt sensitivity.
The endothelins (ET) are a new family of biologically active
peptides that were first detected in the media of cultured
porcine endothelial cells [1]. They are potent vasoconstrictors
when tested on isolated arteries and veins in vitro [1], and cause
a uniquely prolonged increase in arterial blood pressure when
given in pharmacological doses in vivo [1, 2]. Three isoforms of
ET are encoded by the human genome and the most potent one,
ET-l, has been demonstrated to exist in human vascular
endothelial cells [3]. Because of their powerful effects on
vascular smooth muscle cells and their location in endothelial
cells, they have been suggested to participate in the physiologic
regulation of systemic blood pressure and regional blood flow
[1, 3].
The vasoactive properties of ET make them possible candi-
dates for involvement in the pathogenesis of essential hyper-
tension (EHT). Indeed, Saito et at have recently reported
increased plasma levels of ET-l in patients with EHT [41,
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suggesting a causative role for ET- 1 in the pathogenesis of the
disease. However, Davenport et al [5], using different analytical
methods, failed to detect any significant increase in plasma
ET-l levels in his hypertensive patients. Similarly, Suzuki et al
[6], found no increase in plasma ET-1 levels in experimental
hypertension in rats.
To assess the possible role of ET-1 in the pathogenesis of
hypertension and salt sensitivity we measured the concentra-
tions of the peptide in plasma of patients with uncomplicated
essential hypertension and compared them to those of normal
controls. In addition, since ET-l levels in plasma may not
reflect the activity at the tissue level, and since urinary ET-l
excretion has been suggested to serve as a measure of total
ET-1 production [7], we also determined ET-l levels in the
urine of these subjects. Furthermore, since sodium intake has a
marked effect on renal vascular reactivity to exogenous ET-1 in
experimental hypertension [8], the effect of manipulations in
dietary sodium on urinary ET-1 excretion also was investigated.
Methods
Subjects
Seventeen patients (8 men, 9 women, 12 Caucasians, 5
Blacks) previously diagnosed in our clinic as having uncompli-
cated essential hypertension were studied. Nineteen normal
volunteers (7 men, 12 women, 16 Caucasians, 3 Blacks) with no
known hypertensive, or any other disease, served as controls.
All patients stopped medications two weeks prior to the study.
For the assessment of basal excretion rate of ET- 1 on a regular
diet, a 24-hour urine collection and a fasting venous blood
sample were obtained in the morning upon entering the study.
Blood samples were immediately separated and the plasma
stored at —70°C until assayed.
Salt loading
For the assessment of the effect of sodium intake on urinary
ET-l excretion the 17 hypertensive patients were evaluated
during hospitalization at the Clinical Center of the NIH at
Bethesda, Maryland, USA. They were allowed a regular diet
(normal salt) for eight days, then given a low sodium diet
containing 9 mEq/day of NaC1 for eight days, followed by a high
salt diet containing 240 mEq/day, in the form of salt in tablets,
for another eight days. Compliance with the prescribed sodium
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diet was verified in each patient by daily urinary sodium
determinations. Mean blood pressure was determined by aver-
aging three consecutive measurements three times daily. Daily
urine output was collected in plastic bottles containing 30 ml of
6 N hydrochloric acid. Urine samples for ET-l determination on
either low or high salt diets were obtained on the last day of the
corresponding diet. Aliquotes of 2 ml were frozen and stored at
—70°C until assayed.
High-performance liquid chromatography
Radioimmunoassay-coupled high-performance liquid chro-
matography (HPLC) was performed on urine to identify the
molecular forms of ET in the urine. Urine was applied to a C18
column (sBondapak 3.9 x 300 mm, Waters, Millford, Massa-
chusetts, USA) and ET eluted with a linear gradient of 10% to
60% acetonitrile in 0.1% trifluoroacetic acid (TFA) over 40
minutes, at a flow rate of 1 mI/mm. ET-like immunoreactivity
was measured in each one minute fraction. Standards of syn-
thetic isoforms ET-1, ET-2, ET-3 and Big-endothelin (1-38)
were run on the same column only after urine samples were
done.
Radioimmunoassay for ET-1
Immunoreactive ET-l (irET-l) was measured in plasma and
urine samples that were extracted on Sep-Pak C18 cartridges
(Waters Associates). The samples were acidified with an equal
volume of 0.1% TFA and passed over cartridges activated by
acetonitrile. The peptides were eluted with 60% acetonitrile in
0.1% TFA and dried in a vacuum concentrator. The recovery of
ET-l through the extraction phase, as measured by adding
labeled ET- 1 to each sample, was 85 to 92% for both the
hypertensives and the control groups. The reconstituted sam-
ples (100 d) were assayed by a sensitive radioimmunoassay
method using a commercially available kit (Peninsula laborato-
ries, Belmont, California, USA) as previously described [9].
1C50 was 18 pg/tube. According to studies done by the manu-
facturer, cross reactivity with ET-2 and ET-3 was 7% and with
Big-ET 35%. Cross reactivity with unrelated peptides (ANP,
BNP, angiotensin, vasopressin and VIP) was essentially 0%.
Intra-as say and inter-assay coefficients of variance were 7% and
18%, respectively. A dilution curve of urine was roughly
parallel to the standard curve (Fig. 1). ET-l was stable in urine
for at least 24 hours in both controls and hypertensives [10].
Statistical analysis
The data are presented as mean standard error of the mean
(sEM). Statistical analysis was performed using Student's t-test
and analysis of variance (ANOVA) were appropriate. All
statistical computations were done by a statistical package
(Stat View 512+). A P value of less than 0.05 was considered to
represent a statistically significant difference.
Results
There were no significant differences between the hyperten-
sive and the normotensive groups in gender, race, urinary
output, or sodium excretion. The average age was 52 4 in the
hypertensives and 45 3 in the controls (P = NS). Mean
arterial blood pressure (MAP) averaged 107 4 mm Hg in the
hypertensives and 91 2 mm Hg in the controls (P < 0.01).
Creatinine clearance was within normal limits in all hyperten-
sives (mean 96 9 mL/min). Of the control subjects, 11 had a
positive family history for hypertension in one or more first
degree relatives.
irET-l concentrations in plasma were very low, near the limit
of detection, in both the hypertensive and normotensive control
groups. None of the hypertensive patients had an increased
plasma level of ET- 1. The mean plasma concentration of irET- 1
in the hypertensives was 1.3 0.1 pg/ml, and in the controls 1.1
0.3 pg/ml (P = NS).
Reverse-phase HPLC profile of urine is shown in Figure 2.
ET-1-like immunoreactivity eluted as a relatively wide major
peak corresponding to the retention time of synthetic ET- 1. A
small amount of irET- 1 appeared at an early phase near the
solvent front, but no irET-1 was detected at the position of the
precursor of ET- 1, Big-ET, or at any other position. This
indicates that the major component of urinary irET is authentic
ET-1.
In contrast to the very low levels in plasma, irET-1 was
present in high concentrations in all urine samples in both
groups of patients on all types of diet. In the normal controls
there was a marked variability in urinary irET-1 levels, the
mean irET- 1 concentration being 62 11 pg/ml and the daily
excretion rate 109 21 ng/day.
Surprisingly, opposite to the predicted increased levels, and
in contrast to the normal levels of irET-1 in the plasma, the
hypertensive patients had a markedly decreased excretion rate
of the peptide into the urine, compared to the normal controls
(29 3 ng/day, P < 0.001, Fig. 3).
There were no significant correlations between daily irET- 1
excretion and either age, gender, race, urinary output, sodium
excretion or creatinine clearance (r = 0.1, P = NS). Similarly,
there was no correlation between daily irET- 1 excretion and















Fig. 1. Radioimmunoassay for ET-1. Standard curve used for irET-1
determinations in plasma and urine, A urine sample (-I) was serially
diluted and compared to the standard curve (—0—). B/BO- Specific
binding/Total binding.
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Fig. 3. Daily urinary excretion rate (ng/day) of irET-1 in normal
controls and in patients with essential hypertension. < 0.01 for
hypertensives vs. controls.
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Fig. 2. Identity of urinary endothelin. Reverse-phase HPLC of urine 0(A), coupled with RIA for each 1 minute fraction (B) reveals a wide Salt sensitive Salt resistant
major peak corresponding to the retention time of synthetic ET-l(arrow b). No irET was detectable at the position of Big-ET (arrow a). Fig. 4. Effect of changing dietary sodium content on zrET-1 excretion
Retention times of ET-2 and ET-3 were almost indistinguishable from in "salt sensitive" and "salt resistant" hypertensive patients. Note the
ET-l significant difference between the two groups on all types of diets.Symbols are: (U) intermediate (normal) salt diet; () low and (fl) high
salt diets, respectively. *P < 0.05 for salt sensitive vs. salt resistant
hypertensives.
control subjects and hypertensives were grouped together there
was a weak negative correlation between MAP and daily
urinary irET-1 excretion (r =
—0.41, P = 0.01). No correlation irET excretion in these two subgroups is shown in Figure 4. The
was found between a family history of hypertension and urinary amount of dietary sodium had no significant effect on daily
irET-l excretion rate. Likewise, no correlation was found irET-l excretion in any of the patients. However, the rate of
between plasma renin activity and unnary irET- 1. Moreover, urinary irET- 1 excretion in "salt sensitive" patients was signif-
changing dietary sodium, which had marked effects on PRA icantly lower than in "Salt resistant" patients, regardless of salt
(data not shown), had no significant effect on ET-l levels, intake (average 23 3 vs. 36 5 nglday, respectively, P <
The hypertensive patients were further subdivided into two 0.05).
groups according to their blood pressure response to salt
loading [111. When changed from a low sodium to a high sodium Discussion
diet, the MAP in a subset of 10 "salt sensitive" hypertensive In this work we studied whether ET-1 may have a role in the
patients increased more than 8 mm Hg (mean MAP = + 12 mm pathogenesis of hypertension and salt sensitivity by measuring
Hg). In the other seven "salt resistant" hypertensives MAP the concentrations of irET-l in both plasma and urine, and by
increased less than 8 mm Hg (mean LMAP = +1 mm Hg). MAP assessing the effect of sodium intake on urinary irET-1 levels in
while on either normal salt diet or on low salt diet were similar patients with EHT. Our results support those previous reports
in the two subgroups (105 2 and 106 4 mm Hg, respective- that circulating plasma levels of irET- 1 are very low in humans,
ly). in the range of 1 to 2 pg/mI, and are not increased in patients
The effect of changing the salt content in the diet on urinary with essential hypertension [5, 61. The reportedly increased
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plasma levels in hypertensive patients in the study of Saito et al
[4], to the range of 30 pg/mi, may be due to factors like patient
selection (that is, including patients with target organ damage),
or to other methodological differences. It should be noted that
the levels in normal controls, reported in the latter study are
more than 10 times higher than the levels obtained by other
investigators, possibly due to low specificity of the assay.
In sharp contrast to the normal plasma levels, our cohort of
hypertensive patients, had markedly decreased urine levels of
irET-l compared to control subjects. Moreover, the subset of
"salt sensitive" hypertensives had even lower urinary excre-
tion rate of irET-l, under well-controlled similar conditions.
Furthermore, there seems to be a significant, albeit weak,
negative correlation between MAP and urinary irET-1 levels
when data from controls and patients were grouped. These
observations may suggest that there is an inverse relationship
between systemic arterial blood pressure and the rate of urinary
excretion, but not plasma levels, of ET-l.
To understand the mechanism of the observed reduction in
urinary irET-1 levels in hypertension the possible sources of
urinary irET-l should be discussed. These sources could be
either circulating ET- 1, which is filtered by the kidney, or local
production within the kidney. Renal mesangial cells have been
reported to contain mRNA for the precursor of ET-1 and to
release ET-l into the culture media [12]. Likewise, renal
epithelial cells [13], have been shown to synthesize and release
ET, and the renal medulla has been demonstrated to contain
large amounts of irET [14]. On the other hand, the urinary
clearance of ET-1 from the plasma, as determined by clearance
studies of radioiodinated ET-1, is very low [15]. Thus, it is
likely that urinary endothelin excretion reflects renal produc-
tion of the peptide. Therefore, the decreased amounts of
urinary 1rET-1 in patients with essential hypertension represent
a genuine reduction in the rate of production of ET-1 within the
kidney. This reduction in renal ET-l synthesis may be second-
ary to systemic hypertension with high renal perfusion pres-
sure, similar to the pressure-related renin release from the
juxtaglomerular apparatus. However, the possibility that the
decreased renal production of ET-l is a primary phenomenon in
these patients and has an etiologic role in the development of
essential hypertension cannot be excluded. Renal impairment
as a cause of the reduced excretion of ET-1 seems unlikely
because renal disease is reportedly associated with an increase,
rather than a decrease, in renal excretion of ET-l [161.
The physiologic role of ET-l in the kidney is still unknown.
The renal medulla is rich in both irET and binding sites for ET
[17], suggesting that ET may have an autocrine or paracrine
action in the kidney [14]. In addition to well-recognized renal
vascular effects, ET-1 also has glomerular [18], and renal
tubular effects. Perhaps most importantly, it has been suggested
that ET-l has natriuretic properties [19, 20], probably by
inhibition of tubular NaJK-ATPase activity. ET- 1 also inhibits
the vasopressin-induced accumulation of cyclic adenosine
monophosphate in renal collecting ducts [21]. If ET-1 has a role
in the renal handling of sodium and water, as suggested by these
reports, then the low levels of ET-l may have relevance to the
secondary perturbations in renal sodium handling in patients
with hypertension.
Although the low levels of urinary endothelin in hypertension
were not anticipated, they seem to be in agreement with the
reported decrease in renal medullary tissue content of irET- I in
experimental hypertension in animals [14, 22]. The markedly
reduced urinary ET-l levels in our hypertensive patients, the
even lower levels in "salt sensitive" patients, and the low tissue
levels of ET-l in the renal medulla in experimental hyperten-
sion, suggest that the renal endothelin system has a role in the
development and maintenance of clinical hypertension. In
conclusion, patients with essential hypertension, particularly
"salt sensitive" patients, have markedly reduced urinary lev-
els, but normal plasma levels, of irET-1. There is a significant
negative relation between renal excretion of irET-1 and mean
arterial blood pressure. Further studies are needed to examine
the possible causal relationship between the decreased renal
production and excretion of ET- 1 in hypertension and the
pathogenesis of essential hypertension and salt sensitivity.
Reprint requests to Aaron Hoffman, M.D., Transplant Unit, Depart-
ment of Surgery, Rambam Medical Center, Haifa, 31096 Israel.
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